Skip to main content

Table 3 Effect of addition of MRA on final visit renal function and urinary protein/albumin excretion

From: Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Variable Measurement No. of study groups No. patients in intervention No. patients in placebo/control Effect size (95 % CI) I2 (p value)
Creatinine (μmol/L) Final visit 16 601 595 3.83 (−2.14, 9.79) 50.4 % (0.011)
Creatinine Clearance (ml/min) Final visit 6 132 130 −2.51 (−7.05, 2.04) 0.0 % (0.599)
eGFR (ml/min/1.73 m2) Final visit 13 626 617 −2.71 (−4.85, −0.57) 0.0 % (0.727)
GFR (any measure) Final visit 17 692 682 −3.15 (−5.36, −0.95) 0.0 % (0.790)
Urinary ACR (mg/mmol) Final visit 7 355 351 −10.91 (−26.15, 4.32) 83.4 % (0.000)
Urinary PCR (g/g creatinine) Final visit 4 146 150 −0.91 (−1.35, −0.46) 58.4 % (0.065)
24 h urinary albumin excretion (mg/24 h) Final visit 6 151 155 −332.91 (−624.80, −41.02) 66.5 % (0.011)
Change from baseline 3 90 94 −292.23 (−422.19, −162.27) 0.0 % (0.606)
24 h urinary protein excretion (g/24 h) Final visit 2 124 121 −0.41 (−0.90, 0.09) 77.1 % (0.037)